PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16423620-0	2006	NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	lipoprotein lipase	Rattus norvegicus	23-41
16423620-0	2006	NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	uncoupling protein 3	Rattus norvegicus	89-93
16423620-0	2006	NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	9-18	lipoprotein lipase	Rattus norvegicus	23-41
16423620-0	2006	NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	9-18	uncoupling protein 3	Rattus norvegicus	89-93
16311090-0	2005	NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	lipoprotein lipase	Rattus norvegicus	23-41
16311090-0	2005	NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	uncoupling protein 3	Rattus norvegicus	81-101
16311090-0	2005	NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	9-18	lipoprotein lipase	Rattus norvegicus	23-41
16311090-0	2005	NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	9-18	uncoupling protein 3	Rattus norvegicus	81-101
15681896-6	2004	The CYP3A4 mRNA level after exposure to 10 microM NO-1886 was increased by 1.3 times (p<0.05).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	50-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
15681896-7	2004	Further, the CYP3A4 mRNA level after exposure to 50 microM NO-1886 was significantly increased by 3.6 times (p<0.001).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	59-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
15681896-8	2004	However, the CYP3A5 mRNA level after exposure to 50 microM NO-1886 was not significantly increased.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	59-66	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	13-19
32535382-9	2020	Meanwhile, Ibrolipim not only inhibited the upregulation of transforming growth factor-beta1 but also partially reversed the downregulation of matrix metalloproteinase 2, and then prevented extracellular matrix (ECM) accumulation.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	11-20	transforming growth factor beta 1	Homo sapiens	60-92
15012594-5	2004	However, supplementing 1% NO-1886 (200 mg/kg per day) into the high-fat/high-sucrose diet decreased ectopic lipid deposition, improved insulin resistance, and alleviated the beta cell damage.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	26-33	insulin	Sus scrofa	135-142
12236049-0	2002	Effects of the lipoprotein lipase activator NO-1886 as a suppressor agent of atherosclerosis in aorta of mild diabetic rabbits.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	44-51	lipoprotein lipase	Oryctolagus cuniculus	15-33
10443901-0	1999	Lipoprotein lipase promoting agent, NO-1886, modulates adrenal functions: species difference in effects of NO-1886 on steroidogenesis.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	36-43	lipoprotein lipase	Rattus norvegicus	0-18
9440486-4	1998	We administered NO-1886, a lipoprotein lipase activator, to rats bearing Leydig cell tumor and observed its effect on improving the cachexia induced by the tumor.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	16-23	lipoprotein lipase	Rattus norvegicus	27-45
9353574-1	1997	As previously reported, we have discovered that a novel compound, NO-1886 (diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl] benzylphosphonate) has a powerful lipoprotein lipase (LPL) stimulating activity.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	66-73	lipoprotein lipase	Rattus norvegicus	154-172
9353574-1	1997	As previously reported, we have discovered that a novel compound, NO-1886 (diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl] benzylphosphonate) has a powerful lipoprotein lipase (LPL) stimulating activity.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	66-73	lipoprotein lipase	Rattus norvegicus	174-177
9353574-1	1997	As previously reported, we have discovered that a novel compound, NO-1886 (diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl] benzylphosphonate) has a powerful lipoprotein lipase (LPL) stimulating activity.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	75-137	lipoprotein lipase	Rattus norvegicus	154-172
9353574-1	1997	As previously reported, we have discovered that a novel compound, NO-1886 (diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl] benzylphosphonate) has a powerful lipoprotein lipase (LPL) stimulating activity.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	75-137	lipoprotein lipase	Rattus norvegicus	174-177
32535382-8	2020	In addition, Ibrolipim diminished HSFD-induced nicotinamide-adenine dinucleotide phosphate oxidase-4 activation to reduce ROS production, and enhanced the expression and activity of antioxidant enzymes (i.e. superoxide dismutase 1, catalase and glutathione peroxidase 1) to increase ROS elimination, resulting in obvious suppression of renal OS.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	13-22	superoxide dismutase 1	Homo sapiens	208-230
32535382-8	2020	In addition, Ibrolipim diminished HSFD-induced nicotinamide-adenine dinucleotide phosphate oxidase-4 activation to reduce ROS production, and enhanced the expression and activity of antioxidant enzymes (i.e. superoxide dismutase 1, catalase and glutathione peroxidase 1) to increase ROS elimination, resulting in obvious suppression of renal OS.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	13-22	catalase	Homo sapiens	232-240
32535382-9	2020	Meanwhile, Ibrolipim not only inhibited the upregulation of transforming growth factor-beta1 but also partially reversed the downregulation of matrix metalloproteinase 2, and then prevented extracellular matrix (ECM) accumulation.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	11-20	matrix metallopeptidase 2	Homo sapiens	143-169
32535382-8	2020	In addition, Ibrolipim diminished HSFD-induced nicotinamide-adenine dinucleotide phosphate oxidase-4 activation to reduce ROS production, and enhanced the expression and activity of antioxidant enzymes (i.e. superoxide dismutase 1, catalase and glutathione peroxidase 1) to increase ROS elimination, resulting in obvious suppression of renal OS.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	13-22	glutathione peroxidase 1	Homo sapiens	245-269
21762526-0	2011	Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	21-30	lipoprotein lipase	Homo sapiens	80-98
22026163-0	2011	Ibrolipim attenuates high glucose-induced endothelial dysfunction in cultured human umbilical vein endothelial cells via PI3K/Akt pathway.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-9	AKT serine/threonine kinase 1	Homo sapiens	126-129
21762526-9	2011	In contrast, supplementing Ibrolipim into HSFD lowered body weight, plasma glucose, insulin, triglyceride and urinary albumin concentrations while it increased plasma total cholesterol and HDL-C. Ibrolipim suppressed the renal accumulation of triglyceride and cholesterol, and stimulated the diet-induced down-regulation of LPL expression and activity in the kidney.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	27-36	insulin	Homo sapiens	84-91
21762526-9	2011	In contrast, supplementing Ibrolipim into HSFD lowered body weight, plasma glucose, insulin, triglyceride and urinary albumin concentrations while it increased plasma total cholesterol and HDL-C. Ibrolipim suppressed the renal accumulation of triglyceride and cholesterol, and stimulated the diet-induced down-regulation of LPL expression and activity in the kidney.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	27-36	lipoprotein lipase	Homo sapiens	324-327
21762526-9	2011	In contrast, supplementing Ibrolipim into HSFD lowered body weight, plasma glucose, insulin, triglyceride and urinary albumin concentrations while it increased plasma total cholesterol and HDL-C. Ibrolipim suppressed the renal accumulation of triglyceride and cholesterol, and stimulated the diet-induced down-regulation of LPL expression and activity in the kidney.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	196-205	insulin	Homo sapiens	84-91
21762526-9	2011	In contrast, supplementing Ibrolipim into HSFD lowered body weight, plasma glucose, insulin, triglyceride and urinary albumin concentrations while it increased plasma total cholesterol and HDL-C. Ibrolipim suppressed the renal accumulation of triglyceride and cholesterol, and stimulated the diet-induced down-regulation of LPL expression and activity in the kidney.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	196-205	lipoprotein lipase	Homo sapiens	324-327
21762526-10	2011	CONCLUSIONS: Ibrolipim exerts renoprotective and hypolipidemic effects via the increase in renal LPL activity and expression, and thus the increased expression and activity of renal LPL play a vital role in suppressing renal lipid accumulation and ameliorating proteinuria in diet-induced diabetic minipigs.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	13-22	lipoprotein lipase	Homo sapiens	97-100
22026163-10	2011	The lower concentrations (2, 4, 8 microM) of ibrolipim inhibited apoptosis of cultured HUVECs, improved cell viability, down-regulated the mRNA levels of ET-1, vWF, and attenuated the cytotoxicity; however, higher concentration (16, 32 microM) of ibrolipim aggravated the damage of HUVECs cultured under high glucose level.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	45-54	endothelin 1	Homo sapiens	154-158
22026163-10	2011	The lower concentrations (2, 4, 8 microM) of ibrolipim inhibited apoptosis of cultured HUVECs, improved cell viability, down-regulated the mRNA levels of ET-1, vWF, and attenuated the cytotoxicity; however, higher concentration (16, 32 microM) of ibrolipim aggravated the damage of HUVECs cultured under high glucose level.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	45-54	von Willebrand factor	Homo sapiens	160-163
22026163-14	2011	CONCLUSION: Ibrolipim at lower concentrations can inhibit high glucose-induced apoptosis in cultured HUVECs, which might be related to the alternation of Akt activity.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	12-21	AKT serine/threonine kinase 1	Homo sapiens	154-157
21762526-2	2011	The purpose of this study was to observe the preventive effects of Ibrolipim, a LPL activator, on lipid accumulation and LPL expression in the kidneys of minipigs fed a high-sucrose and high-fat diet (HSFD).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	67-76	lipoprotein lipase	Homo sapiens	80-83
21762526-2	2011	The purpose of this study was to observe the preventive effects of Ibrolipim, a LPL activator, on lipid accumulation and LPL expression in the kidneys of minipigs fed a high-sucrose and high-fat diet (HSFD).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	67-76	lipoprotein lipase	Homo sapiens	121-124
19881256-5	2009	In the second stage, we evaluated the levels of CYP1A2 and CYP3A4 gene expression in hepatocytes after exposure to eight NO-1886 (ibrolipim) derivatives.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	121-128	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	48-54
20871621-0	2010	Ibrolipim increases ABCA1/G1 expression by the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-9	ATP binding cassette subfamily A member 1	Homo sapiens	20-25
20871621-0	2010	Ibrolipim increases ABCA1/G1 expression by the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-9	nuclear receptor subfamily 1 group H member 3	Homo sapiens	47-55
20871621-0	2010	Ibrolipim increases ABCA1/G1 expression by the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-9	GLI family zinc finger 2	Homo sapiens	77-82
20871621-7	2010	In addition, LXRalpha was also upregulated by the ibrolipim treatment.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	50-59	nuclear receptor subfamily 1 group H member 3	Homo sapiens	13-21
20871621-8	2010	In addition, LXRalpha small interfering RNA completely abolished the promotion effect that was induced by ibrolipim.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	106-115	nuclear receptor subfamily 1 group H member 3	Homo sapiens	13-21
19881256-5	2009	In the second stage, we evaluated the levels of CYP1A2 and CYP3A4 gene expression in hepatocytes after exposure to eight NO-1886 (ibrolipim) derivatives.	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	130-139	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	48-54
17350593-4	2007	NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	tumor necrosis factor	Mus musculus	153-162
17350593-4	2007	NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	interleukin 6	Mus musculus	165-178
17350593-4	2007	NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	interleukin 6	Mus musculus	180-184
17350593-4	2007	NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	prostaglandin-endoperoxide synthase 2	Mus musculus	191-207
17350593-4	2007	NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2).	4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide	0-7	prostaglandin-endoperoxide synthase 2	Mus musculus	209-214